Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT06981078 is registered in ClinicalTrials.gov with Upstream Bio Inc. as lead sponsor.

NCT NCT06981078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06981078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
Upstream Bio Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 2, 2025
Completion date
November 30, 2027
Enrollment
666 (estimated)
Sites
242

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease